NeuroSense Therapeutics is a biotech company that develops treatments for patients with neurodegenerative diseases. Its product, PrimeC, has completed Phase IIa clinical trials for patients with amyotrophic lateral sclerosis. The company has an upcoming preclinical pipeline including StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.